Medical News
August 19th, 2009
A recent study proclaims that patients who require a blood stem-cell transplant may be able to lessen the risk of graft-versus-host disease (GVHD - transplanted materials attack the body), thanks to ant-T-cell globulin treatment.
August 19th, 2009
The August 19 issue of the Journal of the American Medical Association details a decade-long government led effort to minimize the death rate of hospitalized heart attack patients as well as upgrade the hospital’s execution of these daily emergencies.
August 19th, 2009
A new study believes that drugs that are intended to treat cell surface molecule ERBB3, can provide a more potent way of treating colon cancer.
August 19th, 2009
A Canadian research study states that Avandia, used for the treatment of type 2 diabetes, elevates the risk of heart failure and death more so than Actos.
August 19th, 2009
A new study is looking back to ancient Chinese herbal medicine for contemporary treatment options. The Chinese herb in question referred to as “thunder god vine,” has been shown to minimize inflammation for rheumatoid arthritis patients.
August 19th, 2009
The U.S. FDA and Roche have informed healthcare practitioners that patients being treated with CellCept, have reported cases of Pure Red Cell Aplasia, also known as PRCA.
August 19th, 2009
Although, prGCD, a new drug used to treat patients with a unique genetic disorder - Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.
August 17th, 2009
University of Wisconsin-Madison researchers have published a report detailing their ability to block HIV infections in the lab, using synthetic proteins that prevent the virus from inhabiting healthy cells. The scientist’s synthetic molecules that hinder the HIV protein, gp41, from contacting host cell proteins.
August 17th, 2009
Novartis has recently announced the U.S. FDA approval of their multiple sclerosis treatment drug: Extavia (Interferon beta 1-b). The FDA approved the drug for patients that suffer from a relapse of the auto immune disease, or for those patients whom are newly diagnosed with MS.
August 17th, 2009
After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.
